Navigation Links
Endologix Added to Russell Indexes
Date:6/30/2009

IRVINE, Calif., June 30 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, today announced that it has been added to the Russell 3000(R), Russell 2000(R) and Russell Global Indexes, effective June 26, 2009 after the close of the U.S. markets.

John McDermott, President and CEO, said, "We are pleased that Endologix is now included in the Russell Indexes, which has $4 trillion in assets currently benchmarked to them. The addition should increase the Company's exposure to potential institutional and retail investors as we continue to roll out our new products and increase our share of the abdominal aortic aneurysm market."

The annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes. The Russell 3000 also serves as the U.S. component to the Russell Global Index, which Russell launched in 2007.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4 trillion in assets currently are benchmarked to them.

About Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.

Except for historical information contained herein, this news release contains forward-looking statements with respect to the Company's exposure to potential institutional and retail investors the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding factors that may cause actual results to differ materially from those expressed or implied.

    COMPANY CONTACT:                   INVESTOR CONTACTS:
    Endologix, Inc.                    The Ruth Group
    John McDermott, CEO                Nick Laudico (646) 536-7030
    (949) 595-7200                     Zack Kubow (646) 536-7020
    www.endologix.com


'/>"/>
SOURCE Endologix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Endologix Announces Full Commercial Launch of IntuiTrak Express Delivery System
2. Endologix Receives Nasdaq Letter on Director Independence
3. Endologix Announces Live Web Cast of Presentation in SMH Capital Small Cap Spotlight on June 17, 2009 at 4:15 p.m. ET
4. Corals added to IUCN Red List of Threatened Species for first time
5. Halozyme Therapeutics Added to Nasdaq Biotech Index
6. Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
7. An Event Added to Celebrate and Empower North Carolina Women
8. Blood pressure drug may have added benefit
9. VA Has Added 20 New Vet Centers
10. Turner Investment Partners Added to AHA Diversified Equity Fund
11. Kelsey Grammer, Ben Stiller, Maroon 5 and The Roots Added to COMEDY CENTRALs(R) Live On-air Charity Special Night of Too Many Stars: An Overbooked Concert for Autism Education Hosted by Jon Stewart on Sunday April 13, at 8 p.m. ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... the impact of new federal healthcare regulations at the 7th annual Health IT ... Atlanta. , Andy Slavitt, acting administrator for the Centers for Medicare & Medicaid ...
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway Analytical, ... offering HIAC particle counting and sizing services for USP 788 and 789 particulate ... new service as a response to the needs of pharmaceutical and medical device ...
(Date:12/6/2016)... ... 2016 , ... 'Tis the season for family, festivity, food and fun! Temptation ... season when eating healthy, staying active, and taking medication and doing daily foot health ... , "Shopping trips, parties and family gatherings can take their toll on our ...
(Date:12/6/2016)... ... December 06, 2016 , ... The OSHA ... Training Institute Education Center headquartered in Northern California, has announced the addition of ... safety and health training to public sector employees. , “The primary goal of ...
(Date:12/5/2016)... ... December 05, 2016 , ... Edward Buckingham MD , ... arrival of the newest Sciton laser in January 2017. The Halo is the ... and ablative wavelengths for exceptional results. Outperforming more traditional lasers, the innovative Halo ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Dec. 6, 2016 /PRNewswire/ - InMed Pharmaceuticals, Inc. ... on its R&D program in the use of ... disease (COPD). In June, 2015 InMed initiated its ... identify the targets and potential active compounds that ... Subsequently, with in vitro assays using human lung ...
(Date:12/5/2016)... -- Balloon catheter is an innovative medical device that comprises ... artery in the leg or sometimes into the radial ... These products are generally used to prevent blood vessel ... substances in the blood vessel. In terms of revenue, ... at a CAGR of 3.8% during the forecast period ...
(Date:12/5/2016)... 5, 2016 Spain Glaucoma Surgery Devices Market ... "Spain Glaucoma Surgery Devices Market Outlook to 2022", provides ... market. The report provides value, in millions of US ... market segements - Canaloplasty Micro Catheters and Glaucoma Drainage ... distribution shares data for each of these market segements, ...
Breaking Medicine Technology: